Back to search

Peptide record

TPDB20903

Antibacterial Anticancer Toxicity modified_plain modified
10 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB20903
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia
modified_plain
Yes
A 10-aa modified multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia, with an available 3D structural model.
Modified, details unspecified
Sequence
GXRKXHKXWA
Physicochemical Analysis
C40H63N15O8
NDCEQILMFPSTYV
K
882.04
11.64
4
0
2
+3
1.74
-1.500
10.00
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
5500
623.56
0
Residue Composition
number
1
A
1
R
0
N
0
D
0
C
0
E
0
Q
1
G
1
H
0
I
0
L
2
K
0
M
0
F
0
P
0
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 1 I: 0 L: 0 K: 2 M: 0 F: 0 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
10
C40H63N15O8
882.04
11.64
+3
1.74
-1.500
Evidence Records 6 records
Evidence 1 Activity

Activity

38% Hemolysis
Toxicity
21.3 µg/mL
Hemolytic Cytotoxic
38% Hemolysis | 21.3 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Synergy With Rifampin and Kanamycin Enhances Potency, Kill Kinetics, and Selectivity of De Novo-Designed Antimicrobial Peptides | Antimicrob Agents Chemother | 2010
Evidence 2 Activity

Activity

70% Hemolysis
Toxicity
213 µg/mL
Hemolytic Cytotoxic
70% Hemolysis | 213 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Synergy With Rifampin and Kanamycin Enhances Potency, Kill Kinetics, and Selectivity of De Novo-Designed Antimicrobial Peptides | Antimicrob Agents Chemother | 2010
Evidence 3 Activity

Activity

Toxicity
Hemolytic Cytotoxic
- | NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Synergy with rifampin and kanamycin enhances potency, kill kinetics, and selectivity of de novo-designed antimicrobial peptides. | Antimicrob Agents Chemother | 2010
Evidence 4 Activity

Activity

0% Hemolysis
Toxicity
73.9 µg/mL
Hemolytic Cytotoxic
0% Hemolysis | 73.9 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Synergy with rifampin and kanamycin enhances potency, kill kinetics, and selectivity of de novo-designed antimicrobial peptides. | Antimicrob Agents Chemother | 2010
Evidence 5 Activity

Activity

5% Hemolysis
Toxicity
739 µg/mL
Hemolytic Cytotoxic
5% Hemolysis | 739 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Synergy with rifampin and kanamycin enhances potency, kill kinetics, and selectivity of de novo-designed antimicrobial peptides. | Antimicrob Agents Chemother | 2010
Evidence 6 Activity

Activity

Toxicity
Hemolytic Cytotoxic
- | NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial action of prototypic amphipathic cationic decapeptides and their branched dimers. | Biochemistry | 2009